A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Nov 19, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 20-F for FY2025, filed Feb 4, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the NVS SEC filings page.
Novartis AG (NVS) reported $56.7B in revenue for fiscal year 2025, up 9.6% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 11 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (20-F and 6-K reports).
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group, and the overall is the average of the dimensions that can be computed. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Novartis AG's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Profitability ranks operating companies on their operating margin with gains on asset sales taken out, averaged over the last three fiscal years with the newest counting most, and in smaller part on how steady that margin has been. Novartis AG scores 87/100 on it among other operating companies.
Growth ranks operating companies on the yearly rate at which revenue compounded across the last three fiscal years (the last two where the earliest reports no revenue), counted in the currency each company reports in so that a move in the exchange rate is not read as growth. Novartis AG scores 65/100 on it among other operating companies.
Novartis AG carried $0.62 of long-term debt for every $1 of shareholders' equity at the end of fiscal year 2025, a debt-to-equity ratio of 0.62. With no EBITDA figure for fiscal year 2025, Novartis AG is ranked on that ratio rather than on net debt against EBITDA, a lower ratio being the safer one, and scores 48/100 among other operating companies measured the same way.
Novartis AG held $1.12 of current assets for every $1 of current liabilities at the end of fiscal year 2025, a current ratio of 1.12. Liquidity ranks operating companies on that ratio, and Novartis AG scores 26/100 among other operating companies.
Cash Flow ranks operating companies on their free cash flow margin, which is operating cash flow less capital spending as a share of revenue, averaged over the last three fiscal years with the newest weighted most. Novartis AG scores 95/100 on it among other operating companies.
Returns ranks operating companies on their return on capital employed, which is operating income against total assets less current liabilities, averaged over three fiscal years with the newest weighted most, and in smaller part on how steady that return has been. Novartis AG scores 81/100 on it among other operating companies.
Novartis AG passes 8 of 9 financial strength tests. All 4 profitability signals pass (positive income, cash flow, and earnings quality), 2 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.
For every $1 of reported earnings, Novartis AG generates $1.37 in operating cash flow ($19.1B OCF vs $14.0B net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.
Novartis AG earns $15.42 in operating income for every $1 of interest expense ($17.6B vs $1.1B). This wide margin provides strong safety for debt servicing, even if earnings decline temporarily.
Key Financial Metrics
Earnings & Revenue
Novartis AG generated $56.7B in revenue in fiscal year 2025. This represents an increase of 9.6% from the prior year.
Novartis AG reported $14.0B in net income in fiscal year 2025. This represents an increase of 17.1% from the prior year.
Novartis AG earned $7.15 per diluted share (EPS) in fiscal year 2025. This represents an increase of 21.8% from the prior year.
Not reported for fiscal year 2025.
Cash & Balance Sheet
Novartis AG generated $17.6B in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 8.3% from the prior year.
Novartis AG held $11.4B in cash against $28.7B in long-term debt as of fiscal year 2025.
Not reported for fiscal year 2025.
Margins & Returns
Novartis AG's gross margin was 75.8% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 0.6 percentage points from the prior year.
Novartis AG's operating margin was 31.1% in fiscal year 2025, reflecting core business profitability. This is up 3.0 percentage points from the prior year.
Novartis AG's net profit margin was 24.7% in fiscal year 2025, showing the share of revenue converted to profit. This is up 1.6 percentage points from the prior year.
Novartis AG's ROE was 30.3% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 3.2 percentage points from the prior year.
Capital Allocation
Novartis AG invested $11.2B in research and development in fiscal year 2025. This represents an increase of 11.8% from the prior year.
Novartis AG spent $9.1B on share buybacks in fiscal year 2025, returning capital to shareholders by reducing shares outstanding. This represents an increase of 8.0% from the prior year.
Novartis AG invested $1.5B in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 13.3% from the prior year.
NVS Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2520-F | FY2420-F | FY2320-F | FY2220-F | FY2120-F | FY2020-F | FY1920-F | FY1820-F | FY1720-F | FY1620-F | FY1520-F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $56.7B+9.6% | $51.7B+10.8% | $46.7B+7.4% | $43.5B-1.2% | $44.0B-11.9% | $49.9B+2.5% | $48.7B+5.6% | $46.1B+6.2% | $43.4B-12.2% | $49.4B-1.9% | $50.4B |
| Cost of Revenue | $13.7B+6.8% | $12.8B+2.8% | $12.5B+7.7% | $11.6B-1.3% | $11.7B-22.4% | $15.1B+4.8% | $14.4B-0.6% | $14.5B+6.4% | $13.6B-22.2% | $17.5B+0.7% | $17.4B |
| Gross Profit | $43.0B+10.5% | $38.9B+13.8% | $34.2B+7.2% | $31.9B-1.1% | $32.2B-7.3% | $34.8B+1.5% | $34.3B+8.4% | $31.6B+6.1% | $29.8B-6.7% | $31.9B-3.2% | $33.0B |
| R&D Expenses | $11.2B+11.8% | $10.0B-11.9% | $11.4B+24.0% | $9.2B+6.1% | $8.6B-3.8% | $9.0B-4.5% | $9.4B+10.8% | $8.5B+1.2% | $8.4B-7.2% | $9.0B+1.2% | $8.9B |
| Operating Income | $17.6B+21.3% | $14.5B+48.9% | $9.8B+22.9% | $7.9B-21.0% | $10.1B-0.9% | $10.2B+11.7% | $9.1B+8.1% | $8.4B-3.4% | $8.7B+5.2% | $8.3B-7.9% | $9.0B |
| Interest Expense | $1.1B+13.7% | $1.0B+17.7% | $855.0M+6.9% | $800.0M+1.7% | $787.0M-9.4% | $869.0M+2.2% | $850.0M-8.8% | $932.0M+24.3% | $750.0M+6.1% | $707.0M+7.9% | $655.0M |
| Income Tax | $2.4B+40.2% | $1.7B+208.7% | $551.0M-51.2% | $1.1B-30.6% | $1.6B-10.1% | $1.8B+0.8% | $1.8B+38.5% | $1.3B-19.2% | $1.6B+43.3% | $1.1B+1.2% | $1.1B |
| Net Income | $14.0B+17.1% | $11.9B-19.6% | $14.8B+113.5% | $7.0B-71.0% | $24.0B+197.6% | $8.1B-31.2% | $11.7B-7.0% | $12.6B+63.7% | $7.7B+14.8% | $6.7B-62.3% | $17.8B |
| EPS (Basic) | $7.21+21.8% | $5.92-17.2% | $7.15+124.1% | $3.19-70.2% | $10.71+201.7% | $3.55-30.7% | $5.12-5.9% | $5.44+65.9% | $3.28+16.3% | $2.82-61.9% | $7.40 |
| EPS (Diluted) | $7.15+21.8% | $5.87-17.3% | $7.10+124.0% | $3.17-70.2% | $10.63+202.0% | $3.52-30.4% | $5.06-5.9% | $5.38+65.5% | $3.25+16.1% | $2.80-61.6% | $7.29 |
| Diluted Shares (Avg) | 1.96B-3.9% | 2.04B-2.7% | 2.09B-4.8% | 2.20B-2.8% | 2.26B-1.6% | 2.30B-1.0% | 2.32B-1.1% | 2.34B-1.1% | 2.37B-1.2% | 2.40B-1.6% | 2.44B |
Not reported in any period shown, so not listed: SG&A Expenses, EBITDA.
NVS Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2520-F | FY2420-F | FY2320-F | FY22Filing | FY2120-F | FY2020-F | FY1920-F | FY1820-F | FY1720-F | FY1620-F | FY1520-F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $110.9B+8.5% | $102.2B+2.3% | $99.9B-14.9% | $117.5B-10.9% | $131.8B+3.1% | $127.8B+7.9% | $118.4B-18.7% | $145.6B+9.4% | $133.1B+2.3% | $130.1B | N/A |
| Current Assets | $30.5B+2.5% | $29.7B-2.5% | $30.5B-17.4% | $36.9B-19.3% | $45.7B+54.1% | $29.7B+0.6% | $29.5B-17.0% | $35.6B+26.1% | $28.2B+13.1% | $24.9B | N/A |
| Cash & Equivalents | $11.4B-0.2% | $11.5B-14.4% | $13.4B+78.2% | $7.5B-39.4% | $12.4B+28.5% | $9.7B-13.1% | $11.1B-16.3% | $13.3B+49.8% | $8.9B+26.4% | $7.0B+49.9% | $4.7B |
| Inventory | $6.3B+9.5% | $5.7B-3.2% | $5.9B-17.6% | $7.2B+7.6% | $6.7B-6.5% | $7.1B+19.2% | $6.0B-14.0% | $7.0B+1.3% | $6.9B+9.8% | $6.3B | N/A |
| Goodwill | $25.6B+3.3% | $24.8B+6.1% | $23.3B-20.3% | $29.3B-1.0% | $29.6B-1.3% | $30.0B+13.1% | $26.5B-24.8% | $35.3B+11.2% | $31.8B+2.5% | $31.0B | N/A |
| Total Liabilities | $64.4B+10.8% | $58.1B+9.3% | $53.2B-8.3% | $58.0B-9.3% | $64.0B-10.0% | $71.1B+13.2% | $62.8B-6.1% | $66.9B+13.6% | $58.9B+6.6% | $55.2B | N/A |
| Current Liabilities | $27.3B-4.9% | $28.7B+8.7% | $26.4B-7.9% | $28.7B-5.1% | $30.2B-8.6% | $33.1B+17.0% | $28.3B-4.5% | $29.6B+26.5% | $23.4B+5.4% | $22.2B | N/A |
| Non-Current Liabilities | $37.1B+26.1% | $29.4B+9.8% | $26.8B-8.7% | $29.4B-13.0% | $33.8B-11.3% | $38.1B+10.1% | $34.6B-7.3% | $37.3B+5.1% | $35.4B+7.3% | $33.0B | N/A |
| Long-Term Debt | $28.7B+16.2% | $24.7B+19.9% | $20.6B-8.3% | $22.5B-11.9% | $25.5B-10.5% | $28.5B+27.6% | $22.4B-12.9% | $25.7B+8.8% | $23.6B+30.5% | $18.1B | N/A |
| Total Equity | $46.1B+4.7% | $44.0B-5.6% | $46.7B-21.4% | $59.3B-12.3% | $67.7B+19.5% | $56.6B+2.0% | $55.5B-29.4% | $78.6B+6.0% | $74.2B-0.9% | $74.8B-3.0% | $77.1B |
Not reported in any period shown, so not listed: Short-Term Investments, Accounts Receivable, Long-Term Investments, Retained Earnings.
NVS Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2520-F | FY2420-F | FY2320-F | FY2220-F | FY2120-F | FY2020-F | FY1920-F | FY1820-F | FY1720-F | FY1620-F | FY1520-F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $19.1B+8.7% | $17.6B+21.9% | $14.5B+1.6% | $14.2B-5.5% | $15.1B+10.4% | $13.7B+0.2% | $13.6B-4.5% | $14.3B+13.1% | $12.6B+10.0% | $11.5B-3.5% | $11.9B |
| Capital Expenditures | $1.5B+13.3% | $1.4B+28.9% | $1.1B+15.7% | $916.0M-14.1% | $1.1B-16.4% | $1.3B-7.5% | $1.4B+10.0% | $1.3B-5.4% | $1.3B-28.8% | $1.9B-21.3% | $2.4B |
| Free Cash Flow | $17.6B+8.3% | $16.3B+21.3% | $13.4B+0.6% | $13.3B-4.9% | $14.0B+13.2% | $12.4B+1.1% | $12.2B-5.9% | $13.0B+15.2% | $11.3B+17.5% | $9.6B+0.9% | $9.5B |
| Investing Cash Flow | -$4.9Bn/m | -$7.5B-234.3% | $5.6B+281.2% | $1.5B-65.1% | $4.2Bn/m | -$13.2Bn/m | -$2.2Bn/m | -$5.6Bn/m | -$3.1Bn/m | -$3.4Bn/m | -$10.8B |
| Financing Cash Flow | -$14.9Bn/m | -$11.7Bn/m | -$14.3Bn/m | -$20.6Bn/m | -$16.3Bn/m | -$2.2Bn/m | -$13.6Bn/m | -$4.2Bn/m | -$7.7Bn/m | -$5.3Bn/m | -$9.2B |
| Dividends Paid | $7.8B+2.5% | $7.6B+5.1% | $7.3B-3.3% | $7.5B+1.9% | $7.4B+5.5% | $7.0B+5.1% | $6.6B-4.6% | $7.0B+7.3% | $6.5B+0.3% | $6.5B-2.5% | $6.6B |
| Share Buybacks | $9.1B+8.0% | $8.4B-0.8% | $8.5B-21.9% | $10.9B+273.6% | $2.9B-4.5% | $3.1B-44.5% | $5.5B+179.3% | $2.0B-64.6% | $5.6B+461.9% | $992.0M-83.8% | $6.1B |
Not reported in any period shown, so not listed: Depreciation & Amortization, Stock-Based Compensation.
NVS Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2520-F | FY2420-F | FY2320-F | FY2220-F | FY2120-F | FY2020-F | FY1920-F | FY1820-F | FY1720-F | FY1620-F | FY1520-F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 75.8%+0.6pp | 75.2%+1.9pp | 73.3%-0.1pp | 73.4%0.0pp | 73.3%+3.6pp | 69.7%-0.7pp | 70.4%+1.8pp | 68.5%-0.1pp | 68.6%+4.0pp | 64.6%-0.9pp | 65.5% |
| Operating Margin | 31.1%+3.0pp | 28.1%+7.2pp | 20.9%+2.7pp | 18.3%-4.6pp | 22.9%+2.5pp | 20.3%+1.7pp | 18.7%+0.4pp | 18.2%-1.8pp | 20.1%+3.3pp | 16.7%-1.1pp | 17.8% |
| Net Margin | 24.7%+1.6pp | 23.1%-8.7pp | 31.8%+15.8pp | 16.0%-38.6pp | 54.6%+38.5pp | 16.2%-7.9pp | 24.1%-3.3pp | 27.4%+9.6pp | 17.8%+4.2pp | 13.6%-21.7pp | 35.3% |
| Return on Equity | 30.3%+3.2pp | 27.1%-4.7pp | 31.8%+20.1pp | 11.7%-23.8pp | 35.5%+21.3pp | 14.3%-6.9pp | 21.1%+5.1pp | 16.0%+5.6pp | 10.4%+1.4pp | 9.0%-14.1pp | 23.1% |
| Return on Assets | 12.6%+0.9pp | 11.7%-3.2pp | 14.9%+8.9pp | 5.9%-12.3pp | 18.2%+11.9pp | 6.3%-3.6pp | 9.9%+1.2pp | 8.7%+2.9pp | 5.8%+0.6pp | 5.2% | N/A |
| Current Ratio | 1.12+0.1x | 1.04-0.1x | 1.16-0.1x | 1.29-0.2x | 1.51+0.6x | 0.90-0.1x | 1.04-0.2x | 1.200.0x | 1.21+0.1x | 1.12 | N/A |
| Debt-to-Equity | 0.62+0.1x | 0.56+0.1x | 0.44+0.1x | 0.380.0x | 0.38-0.1x | 0.50+0.1x | 0.40+0.1x | 0.330.0x | 0.32+0.1x | 0.24 | N/A |
| Liabilities-to-Equity | 1.40+0.1x | 1.32+0.2x | 1.14+0.2x | 0.980.0x | 0.95-0.3x | 1.26+0.1x | 1.13+0.3x | 0.85+0.1x | 0.79+0.1x | 0.74 | N/A |
| Asset Turnover | 0.510.0x | 0.510.0x | 0.47+0.1x | 0.370.0x | 0.33-0.1x | 0.390.0x | 0.41+0.1x | 0.320.0x | 0.33-0.1x | 0.38 | N/A |
| FCF Margin | 31.1%-0.4pp | 31.4%+2.7pp | 28.7%-1.9pp | 30.6%-1.2pp | 31.9%+7.1pp | 24.8%-0.4pp | 25.2%-3.1pp | 28.2%+2.2pp | 26.0%+6.6pp | 19.4%+0.5pp | 18.9% |
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Novartis AG NVS | FY2025 | $56.7B | $14.0B | 24.7% | $285.6B | 67/100 |
| AstraZeneca PLC AZN | FY2025 | $58.7B | $10.2B | 17.4% | $272.0B | 63/100 |
| Amgen Inc AMGN | FY2025 | $36.8B | $7.7B | 21.0% | $237.4B | 64/100 |
| Merck & Co., Inc. MRK | FY2025 | $65.0B | $18.3B | 28.1% | $327.4B | 62/100 |
| Gilead Sciences Inc GILD | FY2025 | $29.4B | $8.5B | 28.9% | $206.6B | 66/100 |
| AbbVie Inc. ABBV | FY2025 | $61.2B | $4.2B | 6.9% | $501.0B | 59/100 |
Where Novartis AG Ranks
Frequently Asked Questions
Novartis AG (NVS) reported $56.7B in total revenue for fiscal year 2025. This represents a 9.6% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
Novartis AG (NVS) revenue grew by 9.6% year-over-year, from $51.7B to $56.7B in fiscal year 2025.
Yes, Novartis AG (NVS) reported a net income of $14.0B in fiscal year 2025, with a net profit margin of 24.7%.
As of fiscal year 2025, Novartis AG (NVS) had $11.4B in cash and equivalents against $28.7B in long-term debt.
Novartis AG (NVS) had a gross margin of 75.8% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
Novartis AG (NVS) had an operating margin of 31.1% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
Novartis AG (NVS) had a net profit margin of 24.7% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
Novartis AG (NVS) has a return on equity of 30.3% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
Novartis AG (NVS) generated $17.6B in free cash flow during fiscal year 2025. This represents a 8.3% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
Novartis AG (NVS) generated $19.1B in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
Novartis AG (NVS) had $110.9B in total assets as of fiscal year 2025, including both current and long-term assets.
Novartis AG (NVS) invested $1.5B in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
Novartis AG (NVS) invested $11.2B in research and development during fiscal year 2025.
Novartis AG (NVS) had a current ratio of 1.12 as of fiscal year 2025, which is considered adequate.
Novartis AG (NVS) had a debt-to-equity ratio of 0.62 as of fiscal year 2025. We compute it as long-term debt divided by total shareholder equity, where long-term debt is the noncurrent part of the company's borrowings, so debt due within the next twelve months is not counted.
Novartis AG (NVS) had a liabilities-to-equity ratio of 1.40 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity.
Novartis AG (NVS) had a return on assets of 12.6% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
Novartis AG (NVS) trades at 20.4x earnings, its market capitalization divided by $14.0B net income, FY2025. The market capitalization is $285.6B as of Nov 19, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
Novartis AG (NVS) trades at 5.0x sales, its market capitalization divided by $56.7B revenue, FY2025. The market capitalization is $285.6B as of Nov 19, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
Novartis AG (NVS) has a Piotroski F-Score of 8 out of 9, indicating strong financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Novartis AG (NVS) has an earnings quality ratio of 1.37x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Novartis AG (NVS) has an interest coverage ratio of 15.42x, meaning it can comfortably cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
Novartis AG (NVS) scores 67 out of 100 on our Financial Health Score, indicating strong standing within its operating companies peer group. The score is the average of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.